EXHIBIT 10.11 CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. THE LOCATIONS OF THE OMITTED MATERIALS ARE INDICATED BY THE FOLLOWING NOTATION: [***]. TECHNOLOGY DEVELOPMENT AGREEMENTTechnology Development Agreement • March 7th, 2008 • Allegro Microsystems Inc • Semiconductors & related devices
Amended and Restated Technology Development AgreementTechnology Development Agreement • October 19th, 2007 • Airmedia Group Inc.
NOW, THEREFORE, Party A and Party B, through friendly negotiations and abiding by the principle of equality and mutual benefit, hereby agree as follows:
ContractTechnology Development Agreement • May 28th, 2019
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
TECHNOLOGY DEVELOPMENT AGREEMENT by and between OPGEN, INC., and HITACHI HIGH- TECHNOLOGIES CORPORATION September 25, 2013Technology Development Agreement • March 3rd, 2015 • Opgen Inc • Services-medical laboratories • New York
This TECHNOLOGY DEVELOPMENT AGREEMENT (this “Agreement”) is entered into as of September 25, 2013 (the “Effective Date”) by and between OpGen, Inc., a Delaware corporation having its principal place of business at 708 Quince Orchard Road, Gaithersburg, Maryland 20878 (“OpGen”), and Hitachi High-Technologies Corporation, a Japan corporation having its principal place of business at 24-14, Nishi-shimbashi 1-chome, Minato-ku, Tokyo 105-8717, Japan (“HHT”). OpGen and HHT are sometimes referred to herein individually as a “Party” and collectively as the “Parties” to this Agreement.
EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. TECHNOLOGY DEVELOPMENT AGREEMENT by and between...Technology Development Agreement • April 28th, 2015 • Opgen Inc • Services-medical laboratories • New York
This TECHNOLOGY DEVELOPMENT AGREEMENT (this “Agreement”) is entered into as of September 25, 2013 (the “Effective Date”) by and between OpGen, Inc., a Delaware corporation having its principal place of business at 708 Quince Orchard Road, Gaithersburg, Maryland 20878 (“OpGen”), and Hitachi High-Technologies Corporation, a Japan corporation having its principal place of business at 24-14, Nishi-shimbashi 1-chome, Minato-ku, Tokyo 105-8717, Japan (“HHT”). OpGen and HHT are sometimes referred to herein individually as a “Party” and collectively as the “Parties” to this Agreement.
Technology Development AgreementTechnology Development Agreement • February 13th, 2007 • United National Film Corp • Blank checks
As per the regulation in <Contract Law of People’s Republic Of China>, both parties in the contract sign this contract regarding the project for the development of an integrated platform for fan design and numerical value test after negotiation.
ContractTechnology Development Agreement • February 9th, 2012
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
EXHIBIT 10.27.9 TECHNOLOGY DEVELOPMENT AGREEMENT This Technology Development Agreement (the "Agreement"), dated July 24th, 2002, is by and among Eurotech, Ltd. ("Eurotech"), a District of Columbia corporation with offices located at 10306 Eaton Place,...Technology Development Agreement • August 6th, 2002 • Eurotech LTD • Plastic materials, synth resins & nonvulcan elastomers • New York
FIRST ADDENDUM TO TECHNOLOGY DEVELOPMENT AGREEMENTTechnology Development Agreement • March 3rd, 2015 • Opgen Inc • Services-medical laboratories
This First Addendum to Technology Development Agreement (“Addendum”), dated March 27, 2014 (the “Addendum Effective Date”), is by and between OpGen, Inc., a Delaware corporation having its principal office at 708 Quince Orchard Rd., Gaithersburg, Maryland 20878 (“OpGen”) and Hitachi High-Technologies Corporation, a Japan corporation having its principal place of business at 24-14, Nishi-Shimbashi, 1-chome, Minato-ku, Tokyo 105-8717, Japan (“HHT”), and amends the development work scope and terms of the Technology Development Agreement dated September 25, 2013, by and between OpGen and HHT (the “Development Agreement”). OpGen and HHT are individually referred to as a “Party” and collectively as the “Parties” to this Addendum. All capitalized terms used in this Addendum without definition have the meanings set forth in the Development Agreement.
TECHNOLOGY DEVELOPMENT AGREEMENTTechnology Development Agreement • April 19th, 2023 • Arizona
This Technology Development Agreement (the “Agreement”) is effective as of June 27, 2016 (the “Effective Date”) by and between Eminess Technologies, Inc., an Arizona corporation (“Eminess”), and Nanophase Technologies Corp., a Delaware corporation (“Nanophase”).
TECHNOLOGY DEVELOPMENT AGREEMENTTechnology Development Agreement • October 21st, 2014 • Response Biomedical Corp • Services-testing laboratories
This Technology Development Agreement (this “Technology Development Agreement”) is made and entered into as of October 15, 2014 (the “Effective Date”), by and between Response Biomedical Corp., a corporation organized under the laws of British Columbia and having a place of business at 1781-75th Avenue W., Vancouver, B.C., Canada V6P 6P2 (“Response”), and 杭州中翰盛泰生物技术有限公司, Hangzhou Joinstar Biomedical Technology Co., Ltd., a corporation organized under the laws of People’s Republic of China and having its registered address at Floor 10, Main Building, #519 Xingguo RD, Qianjiang Economic Development Zone, Hangzhou, Zhejiang Province, China (“JBT”). In this Technology Development Agreement, Response and JBT may each be referred to as a “Party” and collectively as the “Parties.”
Technology Development AgreementTechnology Development Agreement • July 18th, 2011 • China Health Industries Holdings, Inc. • Pharmaceutical preparations
Party A entrusts Party B to develop Qunle Xuyuan Tablet (Tentative) and apply for registration on behalf of Party A. With the function of improving hypoxia tolerance, Qunle Xuyuan Tablet is made from Ginkgo Leaf, Gynostemma Pentaphyllum, Puerariae Extract, Panax Quinquefolius, Mint, Cinnamomum Cassia and Amomum Cardamomum etc. Party A shall pay Party B fees and compensations incurred during technology development and registration. Party B accepts the contract and shall undertake to conduct the technology development and apply for registration. Based on mutual negotiation, the parties hereby enter into this agreement (“Agreement”) according to People’s Republic of China Contract Law. Both parties shall abide by the terms in this Agreement.
Technology Development AgreementTechnology Development Agreement • April 28th, 2009 • Airmedia Group Inc. • American depositary receipts
NOW, THEREFORE, Party A and Party B, through friendly negotiations and abiding by the principle of equality and mutual benefit, hereby agree as follows:
TECHNOLOGY DEVELOPMENT AGREEMENTTechnology Development Agreement • December 22nd, 2015 • Hk Battery Technology Inc • Motor vehicle parts & accessories • Delaware
This Fuel cell system Development Agreement is made and entered into this December 17th, 2015 (the “Effective Date”) by and between
RECITALSTechnology Development Agreement • October 10th, 2002 • Goamerica Inc • Radiotelephone communications • Georgia
Technology Development AgreementTechnology Development Agreement • May 16th, 2016 • Airmedia Group Inc. • Services-advertising agencies
This Technology Development Agreement (the “Agreement”) is entered into by and between the following Parties on June 5th, 2015 in Beijing, People’s Republic of China (“China”):
Technology Development AgreementTechnology Development Agreement • October 19th, 2007 • Airmedia Group Inc.
NOW, THEREFORE, Party A and Party B, through friendly negotiations and abiding by the principle of equality and mutual benefit, hereby agree as follows:
TECHNOLOGY DEVELOPMENT AGREEMENT BY AND BETWEEN TWENTE UNIVERSITY AND IMMUNICON CORPORATIONTechnology Development Agreement • December 8th, 2003 • Immunicon Corp • Pennsylvania
This Technology Development Agreement is made as of this first day of April 1997 by and between University of Twente, with its seat at Enschede, P.O. Box 217, 7500 AE. The Netherlands [fax number] (the "Institution") and Immunicon Corporation, a Delaware corporation having offices at 1310 Masons Mill Road, Huntingdon Valley, Pennsylvania 19006 (215) 938 0437fax ("Immunicon").
XXX] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.Technology Development Agreement • October 13th, 2020 • Allegro Microsystems Inc • Semiconductors & related devices • Minnesota
THIS IC TECHNOLOGY DEVELOPMENT AGREEMENT (“Agreement”) is entered into as of May 28, 2009 by and among Polar Semiconductor, Inc., a Delaware corporation headquartered in Bloomington, Minnesota (“PSI”); Sanken Electric Co., Ltd., a Japanese corporation headquartered in Saitama, Japan (“Sanken”); and Allegro MicroSystems, Inc., a Delaware corporation headquartered in Worcester, Massachusetts (“Allegro”). Such parties are singularly referred to herein as a “Party” and collectively referred to as “Parties.”
TECHNOLOGY DEVELOPMENT AGREEMENTTechnology Development Agreement • June 21st, 2018 • Ballard Power Systems Inc. • Electrical industrial apparatus
ContractTechnology Development Agreement • March 1st, 2023 • Hyzon Motors Inc. • Electrical industrial apparatus • Texas
TECHNOLOGY DEVELOPMENT AGREEMENTTechnology Development Agreement • November 21st, 2016 • Kelso Technologies Inc • Railroad equipment
NOW THEREFORE THIS AGREEMENT WITNESSES that, in consideration of the mutual covenants and agreements set forth in this Agreement, and for other good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged by each party), the parties hereby agree as follows:
Technology Development AgreementTechnology Development Agreement • September 14th, 2007 • China Digital TV Holding Co., Ltd.
This Agreement is entered into by the following parties on June 7, 2004 in Beijing, the People’s Republic of China (“the PRC” or “China”):
ContractTechnology Development Agreement • January 3rd, 2018
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
CONNECTED TRANSACTION ANNOUNCEMENT TECHNOLOGY DEVELOPMENT AGREEMENT WITHTechnology Development Agreement • August 15th, 2018
This announcement is made by Alphamab Oncology (the “Company”, together with its subsidiaries, the “Group”) pursuant to the provisions in relation to connected transactions under Chapter 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”).
TECHNOLOGY DEVELOPMENT AGREEMENTTechnology Development Agreement • June 29th, 2017 • NANOPHASE TECHNOLOGIES Corp • Miscellaneous primary metal products • Arizona
This Technology Development Agreement (the “Agreement”) is effective as of June 27, 2016 (the “Effective Date”) by and between Eminess Technologies, Inc., an Arizona corporation (“Eminess”), and Nanophase Technologies Corp., a Delaware corporation (“Nanophase”).
TECHNOLOGY DEVELOPMENT AGREEMENTTechnology Development Agreement • August 14th, 2012 • Celsion CORP • Pharmaceutical preparations • New Jersey
THIS TECHNOLOGY DEVELOPMENT AGREEMENT (the “Agreement”) is executed and effective as of May 7, 2012 (the “Effective Date”), by and between CELSION CORPORATION (“Celsion”), a corporation organized and existing under the laws of the State of Delaware, and Zhejiang Hisun Pharmaceutical Co. Ltd. (“Hisun”), a corporation organized and existing under the laws of China, with offices at 46 Waisha Road, Jiaojiang District, Taizhou City, China and Hisun Pharmaceutical USA Inc., a Delaware corporation, having a place of business located at 212 Carnegie Center, Suite 302, Princeton, New Jersey 08540-6236, in connection with Section 17.16 (“Hisun USA”). Celsion and Hisun are sometimes referred to herein individually as a “Party” and collectively as “Parties”.
Technology Development AgreementTechnology Development Agreement • November 26th, 2007 • ChinaEdu CORP
Technology Development AgreementTechnology Development Agreement • July 18th, 2011 • China Health Industries Holdings, Inc. • Pharmaceutical preparations
Party A entrusts Party B to develop and register the Xinyan 28 Package (Tentative), a skincare product with whitening, moisturizing and anti-aging effect. Party A shall pay Party B fees and compensations incurred during technology development and registration. Party B accepts the contract and shall undertake to conduct the technology development and apply for registration. Based on mutual negotiation, the parties hereby enter into this agreement (“Agreement”) according to People’s Republic of China Contract Law. Both parties shall abide by the terms in this Agreement.
